Drug penetration model of vinblastine-treated Caco-2 cultures

European Journal of Pharmaceutical Sciences

Volumn 41, Issue 1, 2010, Pages 96-106

  Hellinger, Éva ^a   Bakk, Mónika Laura ^a   Pócza, Péter ^b   Tihanyi, Károly ^a   Vastag, Monika ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Absorption; Caco 2; P glycoprotein; Permeability; VB Caco 2; Vinblastine

Indexed keywords

ALPRENOLOL; ATENOLOL; CAFFEINE; CALCEIN; CHLOROTHIAZIDE; CIMETIDINE; CORTICOSTERONE; CYCLOSPORIN A; CYTOCHROME P450; DEXAMETHASONE; DOXORUBICIN; FLUORESCEIN SODIUM; FUROSEMIDE; GLYCOPROTEIN P; IBUPROFEN; KETOCONAZOLE; LABETALOL; LAMOTRIGINE; LOPERAMIDE; LUCIFER YELLOW; PARACETAMOL; PHENAZONE; QUINIDINE; RANITIDINE; SALAZOSULFAPYRIDINE; TERFENADINE; TESTOSTERONE; VERAPAMIL; VINBLASTINE; WARFARIN; ANTINEOPLASTIC AGENT; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG PENETRATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; BIOLOGICAL MODEL; CACO 2 CELL LINE; GENETICS; METABOLISM; POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CACO-2 CELLS; HUMANS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; RNA, MESSENGER; VINBLASTINE;

EID: 77954762783     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.05.015     Document Type: Article

References (57)

1. Anderle P., Niederer E., Rubas W., Hilgendorf C., Spahn-Langguth H., Wunderli-Allenspach H., Merkle H.P., Langguth P. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci. 1998, 87:757-762.
2. Artursson P., Palm K., Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 2001, 46:27-43.
3. Ayrton A., Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 2001, 31:469-497.
4. Balimane P.V., Chong S. Cell culture-based models for intestinal permeability: a critique. Drug Disc. Today 2005, 10:335-343.
5. Balimane P.V., Han Y.H., Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J. 2006, 8:E1-13.
6. Begley D.J. ABC transporters and the blood-brain barrier. Curr. Pharm. Des. 2004, 10:1295-1312.
7. Behrens I., Kissel T. Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers?. Eur. J. Pharm. Sci. 2003, 19:433-442.
8. Bernsdorf A., Giessmann T., Modess C., Wegner D., Igelbrink S., Hecker U., Haenisch S., Cascorbi I., Terhaag B., Siegmund W. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br. J. Clin. Pharmacol. 2006, 61:440-450.
9. Briske-Anderson M.J., Finley J.W., Newman S.M. The influence of culture time and passage number on the morphological and physiological development of Caco-2 cells. Proc. Soc. Exp. Biol. Med. 1997, 214:248-257.
10. Chan L.M., Lowes S., Hirst B.H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 2004, 21:25-51.
11. del Amo E.M., Heikkinen A.T., Mönkkönen J. In vitro-in vivo correlation in P-glycoprotein mediated transport in intestinal absorption. Eur. J. Pharm. Sci. 2009, 36:200-211.
12. Döppenschmitt S., Spahn-Langguth H., Regårdh C.G., Langguth P. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter. Pharm. Res. 1998, 15:1001-1006.
13. Döppenschmitt S., Langguth P., Regårdh C.G., Andersson T.B., Hilgendorf C., Spahn-Langguth H. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J. Pharmacol. Exp. Ther. 1999, 288:348-357.
14. Döppenschmitt S., Spahn-Langguth H., Regårdh C.G., Langguth P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 1999, 88:1067-1072.
15. Eneroth A., Aström E., Hoogstraate J., Schrenk D., Conrad S., Kauffmann H.M., Gjellan K. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci. 2001, 12:205-214.
16. Garberg P., Ball M., Borg N., Cecchelli R., Fenart L., Hurst R.D., Lindmark T., Mabondzo A., Nilsson J.E., Raub T.J., Stanimirovic D., Terasaki T., Oberg J.O., Osterberg T. In vitro models for the blood-brain barrier. Toxicol. In Vitro 2005, 19:299-334.
17. Giessmann T., May K., Modess C., Wegner D., Hecker U., Zschiesche M., Dazert P., Grube M., Schroeder E., Warzok R., Cascorbi I., Kroemer H.K., Siegmund W. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin. Pharmacol. Ther. 2004, 76:192-200.
18. Grès M.C., Julian B., Bourrié M., Meunier V., Roques C., Berger M., Boulenc X., Berger Y., Fabre G. Correlation between oral drug absorption in humans, and apparent drug permeability in TC-7 cells, a human epithelial intestinal cell line: comparison with the parental Caco-2 cell line. Pharm. Res. 1998, 15:726-733.
19. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
20. Hayeshi R., Hilgendorf C., Artursson P., Augustijns P., Brodin B., Dehertogh P., Fisher K., Fossati L., Hovenkamp E., Korjamo T., Masungi C., Maubon N., Mols R., Müllertz A., Mönkkönen J., O'Driscoll C., Oppers-Tiemissen H.M., Ragnarsson E.G., Rooseboom M., Ungell A.L. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur. J. Pharm. Sci. 2008, 35:383-396.
21. Horie K., Tang F., Borchardt R.T. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm. Res. 2003, 20:161-168.
22. Hoskins J., DeHerdt S.V., Moore R.E., Bumol T.F. The development and characterization of Vinca alkaloid-resistant Caco-2 human colorectal cell lines expressing mdr-1. Int. J. Cancer 1993, 20:680-688.
23. Huang S.M., Strong J.M., Zhang L., Reynolds K.S., Nallani S., Temple R., Abraham S., Habet S.A., Baweja R.K., Burckart G.J., Chung S., Colangelo P., Frucht D., Green M.D., Hepp P., Karnaukhova E., Ko H.S., Lee J.I., Marroum P.J., Norden J.M., Qiu W., Rahman A., Sobel S., Stifano T., Thummel K., Wei X.X., Yasuda S., Zheng J.H., Zhao H., Lesko L.J. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 2008, 48:662-670.
24. Hubatsch I., Ragnarsson E.G., Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat. Protoc. 2007, 2:2111-2119.
25. Korjamo T., Honkakoski P., Toppinen M.R., Niva S., Reinisalo M., Palmgrén J.J., Mönkkönen J. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur. J. Pharm. Sci. 2005, 26:266-279.
26. Korjamo T., Mönkkönen J., Uusitalo J., Turpeinen M., Pelkonen O., Honkakoski P. Metabolic and efflux properties of Caco-2 cells stably transfected with nuclear receptors. Pharm. Res. 2006, 23:1991-2001.
27. Kusuhara H., Suzuki H., Terasaki T., Kakee A., Lemaire M., Sugiyama Y. P-glycoprotein mediates the efflux of quinidine across the blood-brain barrier. J. Pharmacol. Exp. Ther. 1997, 283:574-580.
28. Laska D.A., Houchins J.O., Pratt S.E., Horn J., Xia X., Hanssen B.R., Williams D.C., Dantzig A.H., Lindstrom T. Characterization and application of a vinblastine-selected CACO-2 cell line for evaluation of p-glycoprotein. In Vitro Cell Dev. Biol. Anim. 2002, 38:401-410.
29. Lennernäs H. Human intestinal permeability. J. Pharm. Sci. 1998, 87:403-410.
30. Lentz K.A., Polli J.W., Wring S.A., Humphreys J.E., Polli J.E. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm. Res. 2000, 17:1456-1460.
31. Lin J.H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Deliv. Rev. 2003, 55:53-81.
32. Lin J.H. How significant is the role of P-glycoprotein in drug absorption and brain uptake?. Drugs Today 2004, 40:5-22.
33. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin Phenol reagent. J. Biol. Chem. 1951, 193:265-275.
34. Masuda S., Uemoto S., Goto M., Fujimoto Y., Tanaka K., Inui K. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin. Pharmacol. Ther. 2004, 75:352-361.
35. Mitin T., Von Moltke L.L., Court M.H., Greenblatt D.J. Levothyroxine up-regulates P-glycoprotein independent of the pregnane×receptor. Drug Metab. Dispos. 2004, 32:779-782.
36. Mizuno N., Niwa T., Yotsumoto Y., Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 2003, 55:425-461.
37. Murakami T., Takano M. Intestinal efflux transporters and drug absorption. Expert Opin. Drug Metab. Toxicol. 2008, 4:923-939.
38. Neuhoff S., Ungell A.L., Zamora I., Artursson P. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 2003, 20:1141-1148.
39. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., Serabjit-Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 2001, 299:620-628.
40. Sadeque A.J., Wandel C., He H., Shah S., Wood A.J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 2000, 68:231-237.
41. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin and cyclosporin A. J. Clin. Investig. 1995, 96:1698-1705.
42. Schinkel A.H., Wagenaar E., Mol C.A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Investig. 1996, 97:2517-2524.
43. Schwab D., Fischer H., Tabatabaei A., Poli S., Huwyler J. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J. Med. Chem. 2003, 46:1716-1725.
44. Shirasaka Y., Kawasaki M., Sakane T., Omatsu H., Moriya Y., Nakamura T., Sakaeda T., Okumura K., Langguth P., Yamashita S. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport. Drug Metab. Pharmacokinet. 2006, 21:414-423.
45. Shirasaka Y., Sakane T., Yamashita S. Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane. J. Pharm. Sci. 2008, 97:553-565.
46. Siissalo S., Laitinen L., Koljonen M., Vellonen K.S., Kortejärvi H., Urtti A., Hirvonen J., Kaukonen A.M. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur. J. Pharm. Biopharm. 2007, 67:548-554.
47. Skolnik S., Lin X., Wang J., Chen X.H., He T., Zhang B. Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J. Pharm. Sci. 2010, 99:3246-3265.
48. Smith N.F., Mani S., Huang H., Bates S.E., Figg W.D., Sparreboom A. Induction of cytochrome P450 3A4 (CYP3A4) by vinblastine. Clin. Pharmacol. Ther. 2006, 79:35. (Abstract).
49. Suzuki H., Sugiyama Y. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur. J. Pharm. Sci. 2000, 12:3-12.
50. Thummel K.E., Brimer C., Yasuda K., Thottassery J., Senn T., Lin Y., Ishizuka H., Kharasch E., Schuetz J., Schuetz E. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol. Pharmacol. 2001, 60:1399-1406.
51. Troutman M.D., Thakker D.R. Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm. Res. 2003, 20:1200-1209.
52. Ungell A.L., Karlsson J. Cell cultures in drug discovery: An industrial perspective. Drug Bioavailability. Estimation of Solubility, Permeability, Absorption and Bioavailability 2003, 90-131. Wiley-VCH, Weinheim. H. van de Waterbeemd, H. Lennernas, P. Artursson (Eds.).
53. Ungell A.L. Caco-2 replace or refine?. Drug Discov. Today: Technol. 2004, 1:423-430.
54. Volpe D.A. Variability in Caco-2 and MDCK cell-based intestinal permeability assays. J. Pharm. Sci. 2008, 97:712-725.
55. Walter E., Kissel T. Heterogeneity in the human intestinal cell line Caco-2 leads to differences in the transepithelial transport. Eur. J. Pharm. Sci. 1995, 3:215-230.
56. Westphal K., Weinbrenner A., Zschiesche M., Franke G., Knoke M., Oertel R., Fritz P., von Richter O., Warzok R., Hachenberg T., Kauffmann H.M., Schrenk D., Terhaag B., Kroemer H.K., Siegmund W. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin. Pharmacol. Ther. 2000, 68:345-355.
57. Zhao Y.H., Le J., Abraham M.H., Hersey A., Eddershaw P.J., Luscombe C.N., Butina D., Beck G., Sherborne B., Cooper I., Platts J.A. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J. Pharm. Sci. 2001, 90:749-784.